METTL17

Across TCGA pan-cancer cohorts, METTL17 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of METTL17’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where METTL17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types METTL17 is over-expressed in tumor, although a few such as BRCA and PRAD show the opposite, repressed pattern.

BLCA, HNSC, and LIHC are the cancer types where METTL17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in METTL17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	All	+0.870	<.001	9	view →
HNSC	All	III,IV	+0.504	<.001	9	view →
LIHC	Female	II,III,IV	+1.035	<.001	8	view →
UCEC	All	II,III,IV	+0.775	<.001	6	view →
STAD	All	II,III,IV	+0.638	<.001	6	view →
CHOL	All	All	+1.623	<.001	5	view →
LUSC	Male	All	+0.499	<.001	4	view →
COAD	All	II,III,IV	+0.319	.005	4	view →
BRCA	Female	All	−0.195	.006	4	view →
ESCA	All	All	+0.787	<.001	3	view →
LUAD	Female	All	+0.429	<.001	3	view →
KIRP	All	II,III,IV	+0.344	.036	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

METTL17–BLCA

Open the BLCA breakdown →